Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14968000 | 1.00 | TSHR (0.50) | TSHRMEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL16109793 | 0.92 | TSHR (0.43) | TSHRMEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL16109525 | 0.90 | TSHR (0.46) | TSHRMEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL14967217 | 0.88 | LMNA (0.46) | TSHRALDH1A1GAA | |
| SCHEMBL14966866 | 0.87 | LMNA (0.40) | TSHRMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL14967420 | 0.85 | TSHR (0.46) | TSHRMEN1KMT2ACYP2C19L3MBTL1 | |
| SCHEMBL16109704 | 0.84 | LMNA (0.41) | TSHRMEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL16109148 | 0.84 | PPARG (0.50) | TSHRL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL14967940 | 0.83 | ALDH1A1 (0.47) | TSHRMEN1KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL14968305 | 0.83 | PPARG (0.52) | TSHRMEN1KMT2ACYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040698-B2 | Method for preparing optically pure (+)-ambrisentan and (+)-darusentan | INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-26 | — | — | US | disclosed |
| US-9040698-B2 | Method for preparing optically pure (+)-ambrisentan and (+)-darusentan | INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-26 | — | — | US | disclosed |
| US-9040698-B2 | Method for preparing optically pure (+)-ambrisentan and (+)-darusentan | INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-26 | — | — | US | disclosed |
| US-20140249309-A1 | Method for Preparing Optically Pure (+)-Ambrisentan and (+)-Darusentan | INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2014-09-04 | — | — | US | disclosed |
| US-20140249309-A1 | Method for Preparing Optically Pure (+)-Ambrisentan and (+)-Darusentan | INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2014-09-04 | — | — | US | disclosed |
| US-20140249309-A1 | Method for Preparing Optically Pure (+)-Ambrisentan and (+)-Darusentan | INSTITUTE OF CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2014-09-04 | — | — | US | disclosed |
| US-20130317044-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE | ABBOTT GMBH & CO. KG (DE) | 2013-11-28 | — | — | US | disclosed |
| US-8349843-B2 | Carboxylic acid derivatives, their preparation and use | ABBOTT GMBH & CO. KG (DE) | 2013-01-08 | — | — | US | disclosed |
| US-20120088911-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE | ABBOTT GMBH & CO. KG (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20110178294-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE | ABBOTT GMBH & CO. KG (DE) | 2011-07-21 | — | — | US | disclosed |
| US-20060160808-A1 | New carboxylic acid derivatives, their preparation and their use | ROYALTY PHARMA COLLECTION TRUST | 2006-07-20 | — | — | US | disclosed |
| US-20040092742-A1 | Novel carboxylic acid derivatives, their preparation and use | ABBOTT GMBH & CO. KG | 2004-05-13 | — | — | US | disclosed |
| US-6600043-B2 | Pyramidine or triazine derivatives which specifically inhibit the binding of endothelin to the receptor | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-29 | — | — | US | disclosed |
| US-20020052495-A1 | Novel carboxylic acid derivatives, their preparation and use | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-05-02 | — | — | US | disclosed |
| US-6197958-B1 | CYCLOPENTAPYRIMIDINE DERIVATIVES; ENDOTHELIN RECEPTOR INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-06 | — | — | US | disclosed |
| US-6030975-A | ANTAGONIST OF ENDOTHELINS, I.E. INHIBITION OF BINDING WITH RECEPTOR; ANTITUMOR AND -CARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| EP-0969841-A1 | USE OF CARBOXYLIC ACID DERIVATIVES FOR TREATING CANCER | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-12 | — | — | EP | disclosed |
| US-5969134-A | CARDIOVASCULAR DISORDERS, VASOCONSTRICTION, HYPOTENSIVE AGENTS AND RELEASE OF ENDOTHELINS | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-19 | — | — | US | disclosed |
| US-5932730-A | Carboxylic acid derivatives, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-03 | — | — | US | disclosed |
| WO-1998041206-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE IN TREATING CANCER | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088911-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE | HCAR1, HCAR2, HCAR3 | TSHR 922/4885MEN1 3517/4885KMT2A 2424/4885 |
| US-20020052495-A1 | Novel carboxylic acid derivatives, their preparation and use | HCAR1, HCAR2, SUCNR1 | TSHR 1474/4885MEN1 3402/4885KMT2A 2416/4885 |
| US-20130317044-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE | HCAR1, HCAR2, HCAR3 | TSHR 938/4885MEN1 3333/4885KMT2A 2152/4885 |
| US-20140249309-A1 | Method for Preparing Optically Pure (+)-Ambrisentan and (+)-Darusentan | AKR1D1, AKR1C2, AKR1C1 | TSHR 1181/4885MEN1 2018/4885KMT2A 3912/4885 |
| US-20040092742-A1 | Novel carboxylic acid derivatives, their preparation and use | HCAR1, HCAR2, SUCNR1 | TSHR 1474/4885MEN1 3402/4885KMT2A 2416/4885 |
| US-20110178294-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE | HCAR1, HCAR2, HCAR3 | TSHR 938/4885MEN1 3333/4885KMT2A 2152/4885 |
| US-20060160808-A1 | New carboxylic acid derivatives, their preparation and their use | CYP2C19, CYP2C9, ABCG2 | TSHR 3288/4885MEN1 2504/4885KMT2A 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.